Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P1236: EFFICACY AND TOXICITY F...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
P1236: EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA

P1236: EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA

Bibliographic Details
Main Authors: K. Hu, F. Yang, H. Shi, R. Liu, P. Zheng, S. Feng, Y. Guo
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000847808.59949.f6
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000847808.59949.f6

Similar Items

  • Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
    by: Jin Zhou, et al.
    Published: (2022-09-01)
  • P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
    by: Y. Zhang, et al.
    Published: (2022-06-01)
  • Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
    by: Jiaying Wu, et al.
    Published: (2022-05-01)
  • Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma
    by: Colton Ladbury, MD, et al.
    Published: (2024-04-01)
  • An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
    by: Bin Xue, et al.
    Published: (2025-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs